Physician profile
Rui E Teng
NPI 1104028067
$38,711.34
in general payments reported to CMS, 2019-2025
42 companies · $5,659 in 2025
The $5,659 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $2,509 · 2021: $3,712 · 2022: $4,436 · 2023: $4,598 · 2024: $7,298 · 2025: $5,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,555.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,207.91 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Gilead Sciences, INC. | $4,881.11 | 2019-2025 | Vemlidy, Livdelzi |
| Glaxosmithkline, LLC. | $3,424.65 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $3,067.11 | 2019-2025 | Creon, Linzess, Ubrelvy |
| Amgen INC. | $3,054.18 | 2019-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,974.77 | 2020-2025 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $2,545.91 | 2019 | |
| Novo Nordisk INC | $2,057.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,820.25 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $1,300.28 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $1,194.78 | 2019-2023 | |
| Lilly USA, LLC | $878.09 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $579.14 | 2019-2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $475.01 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $468.45 | 2019-2023 | Verquvo, Belsomra, Steglatro |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rui Teng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.